DK1648431T3 - Anvendelse af en polyaminfattig sammensætning til fremstilling af et medicinsk levnedsmiddel til mennesker - Google Patents

Anvendelse af en polyaminfattig sammensætning til fremstilling af et medicinsk levnedsmiddel til mennesker

Info

Publication number
DK1648431T3
DK1648431T3 DK04767761T DK04767761T DK1648431T3 DK 1648431 T3 DK1648431 T3 DK 1648431T3 DK 04767761 T DK04767761 T DK 04767761T DK 04767761 T DK04767761 T DK 04767761T DK 1648431 T3 DK1648431 T3 DK 1648431T3
Authority
DK
Denmark
Prior art keywords
pain
diet
group
low
polyamine
Prior art date
Application number
DK04767761T
Other languages
Danish (da)
English (en)
Inventor
Jacques-Philippe Moulinoux
Guy Simonnet
Original Assignee
Univ Rennes
Univ Victor Segalen Bordeaux I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rennes, Univ Victor Segalen Bordeaux I filed Critical Univ Rennes
Application granted granted Critical
Publication of DK1648431T3 publication Critical patent/DK1648431T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pediatric Medicine (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
DK04767761T 2003-07-31 2004-07-22 Anvendelse af en polyaminfattig sammensætning til fremstilling af et medicinsk levnedsmiddel til mennesker DK1648431T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0309480A FR2858231B1 (fr) 2003-07-31 2003-07-31 Utilisation nouvelle d'une composition alimentaire a usage humain pauvre en polyamines pour la realisation d'un aliment therapeutique
PCT/FR2004/001962 WO2005020974A1 (fr) 2003-07-31 2004-07-22 Utilisation nouvelle d’une composition pauvre en polyamines pour la realisation d’un aliment therapeutique humain

Publications (1)

Publication Number Publication Date
DK1648431T3 true DK1648431T3 (da) 2009-09-14

Family

ID=34043717

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04767761T DK1648431T3 (da) 2003-07-31 2004-07-22 Anvendelse af en polyaminfattig sammensætning til fremstilling af et medicinsk levnedsmiddel til mennesker

Country Status (11)

Country Link
US (1) US9023417B2 (es)
EP (1) EP1648431B1 (es)
JP (2) JP2007500687A (es)
AT (1) ATE432695T1 (es)
CA (1) CA2533690C (es)
DE (1) DE602004021382D1 (es)
DK (1) DK1648431T3 (es)
ES (1) ES2331613T3 (es)
FR (1) FR2858231B1 (es)
HK (1) HK1092696A1 (es)
WO (1) WO2005020974A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896127B1 (fr) * 2006-01-17 2008-04-11 Univ Rennes I Etablissement Pu Utilisation nouvelle d'une composition alimentaire a usage humain ou veterinaire pauvre en polyamines pour la realisation d'un aliment therapeutique
FR2967868B1 (fr) * 2010-11-30 2012-11-09 Univ Dauvergne Clermont I Utilisation d'une composition alimentaire dans le traitement et/ou la prevention des douleurs neuropathiques induites par un agent anticancereux
FR2979241B1 (fr) 2011-08-30 2014-05-09 Nutrialys Medical Nutrition Sa Utilisation de compositions a faible teneur en polyamines dans la prevention ou le traitement des effets indesirables lies a un traitement anti-cancereux
FR2980709B1 (fr) * 2011-09-29 2013-10-25 Nutrialys Medical Nutrition Sa Compositions contenant de la spermine et compositions pharmaceutiques les contenant
FR2985427B1 (fr) * 2012-01-10 2016-07-15 Nutrialys Medical Nutrition Sa Compositions contenant de l'agmatine et leurs utilisations dans la preparation de medicaments ou de substances nutraceutiques
EA028069B1 (ru) * 2014-05-30 2017-10-31 Общество с ограниченной ответственностью "Лактокор" Пептид, обладающий ноотропным действием, композиции на его основе и способы их применения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2706255B1 (fr) * 1993-06-17 1995-10-27 Univ Rennes Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
FR2706254B1 (fr) * 1993-06-17 1995-08-25 Univ Rennes Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines.
US5677349A (en) * 1995-04-27 1997-10-14 Gilad; Gad M. Agmatine for the treatment of neurotrauma and neurodegenerative diseases
US20030013772A1 (en) * 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
CA2318004A1 (en) * 1999-09-15 2001-03-15 Oridigm Corporation Novel polyamine analogues as therapeutic and diagnostic agents

Also Published As

Publication number Publication date
US9023417B2 (en) 2015-05-05
DE602004021382D1 (de) 2009-07-16
CA2533690C (en) 2013-06-11
EP1648431B1 (fr) 2009-06-03
CA2533690A1 (en) 2005-03-10
US20070184151A1 (en) 2007-08-09
FR2858231B1 (fr) 2006-02-10
JP2012144540A (ja) 2012-08-02
FR2858231A1 (fr) 2005-02-04
EP1648431A1 (fr) 2006-04-26
ES2331613T3 (es) 2010-01-11
HK1092696A1 (en) 2007-02-16
WO2005020974A1 (fr) 2005-03-10
JP2007500687A (ja) 2007-01-18
JP5501395B2 (ja) 2014-05-21
ATE432695T1 (de) 2009-06-15

Similar Documents

Publication Publication Date Title
Henter et al. Novel glutamatergic modulators for the treatment of mood disorders: current status
Frampton et al. Pregabalin: in the treatment of painful diabetic peripheral neuropathy
Dézsi et al. Safinamide for the treatment of Parkinson's disease
Schapira et al. Levodopa in the treatment of Parkinson’s disease
HK1092696A1 (en) Novel use of a polyamine-poor composition for the production of a medical human food
Wood The co-agonist concept: is the NMDA-associated glycine receptor saturated in vivo?
Mittur et al. Pharmacokinetics of Rytary®, an extended-release capsule formulation of carbidopa–levodopa
McDougall et al. Effects of ketamine on the unconditioned and conditioned locomotor activity of preadolescent and adolescent rats: impact of age, sex, and drug dose
EP3192506A3 (en) Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative or 5-aminolevulinic acid as active ingredient
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
DE60330542D1 (de) Pharmazeutische Zubereitung enthaltend einen NMDA Rezeptor Agonisten für die Behandlung von Bewegungsstörungen
AR036943A1 (es) Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
WO2008096775A1 (ja) 疼痛疾患治療剤
Elsworth et al. The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties
HRP20141234T1 (hr) Tapentadol za tretiranje boli od artritisa
HRP20240115T1 (hr) Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom
Lapouble et al. Phosphinothricin induces epileptic activity via nitric oxide production through NMDA receptor activation in adult mice
EP1171114B1 (en) Method for the treatment of incontinence
Zarrindast et al. Role of nitric oxide in the acquisition and expression of apomorphine-or morphine-induced locomotor sensitization
Raziya Banu et al. Ameliorative effect of Withaferin A on ageing-mediated impairment in the dopamine system and its associated behavior of Wistar Albino Rat
Dézsi et al. Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs
Head et al. The effects of L-deprenyl on spatial short term memory in young and aged dogs
UA102547C2 (uk) Тверда фармацевтична композиція
Javitt et al. Inhibition of striatal dopamine release by glycine and glycyldodecylamide
Jacobs Dietary creatine monohydrate supplementation.